Api Holdings (Pharmeasy) Profitability Turnaround Story

For years, PharmEasy was known for rapid growth, aggressive expansion, and mounting losses. However, FY26 may be a turning point for its parent company, API Holdings. Has the company finally cracked the profitability puzzle, or is the journey far from over? Let's break down the numbers behind API Holdings' FY26 performance and what they reveal about PharmEasy profitability.

What do API Holdings do?

API Holdings connects healthcare manufacturers, hospitals, pharmacies, diagnostic centres, and consumers through a combination of technology platforms and healthcare infrastructure. 

The company owns well-known healthcare brands such as PharmEasy, Thyrocare, Ascent, and Aknamed. Its operations are spread across three key segments:

• B2B Distribution: Supplies medicines and healthcare products to pharmacies, retailers, hospitals, and institutions through Ascent and Aknamed.

• B2C Digital Healthcare: Operates PharmEasy, offering online medicine delivery, diagnostics booking, and healthcare services.

• Diagnostics: Runs Thyrocare, providing pathology tests, health check-ups, and home sample collection services.

API Holdings FY26 Financial Performance Analysis

A. Revenue Growth Remained Strong

Source: API Holdings Financial Report

Revenue increased by Rs 859.1 crore during FY26, driven by growth across PharmEasy (B2C), Thyrocare Diagnostics and the B2B distribution business. Hence, growth could indicate continued demand across healthcare services, medicines, and diagnostics despite a challenging operating environment.

B. Gross Profit Improved Faster Than Revenue

Gross profit grew faster than revenue, reflecting an upside of around 21.9%. It reflects a better product mix, improved pricing discipline and increasing contribution from high-margin businesses like Thyrocare. This could be one of the most important positives for investors.

C. Operating Costs Came Under Control

Despite revenue growing 14%, operating expenses declined. This suggests a strong cost rationalisation, better operating efficiency and benefits from restructuring efforts over the last few years.

D. EBITDA Turned Positive

This is arguably the most important development in FY26. So, API Holdings moved from a loss of Rs. 231 cr recovered to EBITDA profits of Rs. 62.5 cr in FY '26. But what happened that it got such a positive turning point?

From Rs 231 cr Loss to Rs 62 cr. Profit: What Changed At API Holding?

The recovery was driven by a mix of stronger margins, cost optimisation, and improving performance across key business segments. 

1. Gross Profit Expanded Significantly:

Gross profit grew even faster, rising by 22%, adding Rs. 245 cr in business. It could show procurement efficiencies and a higher contribution from profitable businesses like Thyrocare. 

2. Operating Costs Were Brought Under Control:

A reduction of over Rs. 62 cr is seen in cost, which could be due to restructuring efforts, despite being revenue on the higher side.

3. B2B Business Reached Break-even:

The B2B distribution segment turned an EBITDA loss of Rs. 109 cr into a profit of Rs. 1 cr. 

4. PharmEasy Continued to Improve:

While PharmEasy still has a loss-making but significantly improved EBITDA loss from Rs.86 cr to Rs.39 cr in FY26

5. Aknamed's Cost Optimization Paid Off:

Aknamed's revenue remained largely flat, but its EBITDA loss reduced sharply from Rs 94 cr to Rs 14 cr in FY26

6. Thyrocare Remained the Profit Engine:

Thyrocare revenue grew 20.6%, while EBITDA increased from Rs.210 cr to Rs.280 cr in FY26. The diagnostics business alone generated profits that helped offset losses in other segments. 

E. Finance Costs Declined Sharply

Lower debt servicing costs helped reduce overall losses and improve cash flow flexibility.

F. Working Capital Efficiency Improved

The improvement may appear small, but it shows better inventory and receivables management across businesses.

Revenue Breakdown Of API Holdings

At first, API Holdings could appear heavily dependent on its B2B distribution business, which generates the majority of its revenue. While B2B brings volume, businesses like Thyrocare and PharmEasy are becoming increasingly important for improving margins and long-term profitability. 

Here, the revenue mix could show that API Holdings is no longer relying on a single business for growth. Instead, it is coming from diagnostics, digital healthcare, and distribution, which might give the company multiple levers to expand. l. 

Thyrocare continues to grow faster than the overall company. At the same time, PharmEasy's improving performance reflects that earlier restructuring efforts may likely be starting to deliver results. 

Also Read: API Holdings 9MFY26 Financial Analysis, The Actual Story